Watson, Synthon in biosimilar deal
13:44 EDT 18 Jul 2012 | BioCentury
Synthon B.V. (Nijmegen, the Netherlands) granted Watson Pharmaceuticals Inc. (NYSE:WPI) worldwide rights to a biosimilar of breast and gastric cancer drug Herceptin trastuzumab that has completed a European Phase I trial. Watson will develop the prod..
Original Article: Watson, Synthon in biosimilar deal
More From BioPortfolio on "Watson, Synthon in biosimilar deal"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
